相似文献
1
Immunological Backbone of Uveal Melanoma: Is There a Rationale for Immunotherapy?
Cancers (Basel). 2019 Jul 26;11(8):1055. doi: 10.3390/cancers11081055.
2
Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Eur J Cancer. 2017 Sep;82:56-65. doi: 10.1016/j.ejca.2017.05.038. Epub 2017 Jun 22.
3
Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
J Immunother Cancer. 2018 Feb 12;6(1):13. doi: 10.1186/s40425-018-0322-1.
4
Role of immune checkpoint inhibitors and novel immunotherapies in uveal melanoma.
Chin Clin Oncol. 2018 Feb;7(1):8. doi: 10.21037/cco.2018.01.05.
5
Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies.
Curr Oncol Rep. 2017 Jul;19(7):45. doi: 10.1007/s11912-017-0606-5.
6
Radiation and systemic immunotherapy for metastatic uveal melanoma: a clinical retrospective review.
Front Oncol. 2024 Jul 4;14:1406872. doi: 10.3389/fonc.2024.1406872. eCollection 2024.
7
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29.
8
Immune checkpoint blockade for unresectable or metastatic uveal melanoma: A systematic review.
Cancer Treat Rev. 2017 Nov;60:44-52. doi: 10.1016/j.ctrv.2017.08.009. Epub 2017 Aug 24.
9
A major responder to ipilimumab and nivolumab in metastatic uveal melanoma with concomitant autoimmunity.
Pigment Cell Melanoma Res. 2017 Jan;30(6):558-562. doi: 10.1111/pcmr.12607. Epub 2017 Jul 23.
10
Pembrolizumab as first-line treatment for metastatic uveal melanoma.
Cancer Immunol Immunother. 2019 Jul;68(7):1179-1185. doi: 10.1007/s00262-019-02352-6. Epub 2019 Jun 7.
引用本文的文献
1
Long-term risk of de novo malignancy with tumor necrosis factor alpha (TNF) inhibitor immunosuppression: a multicenter, retrospective cohort study.
J Inflamm (Lond). 2025 Aug 14;22(1):34. doi: 10.1186/s12950-025-00445-x.
2
Malignant melanoma complicated with cataract and secondary glaucoma: A case report.
Oncol Lett. 2024 Aug 30;28(5):520. doi: 10.3892/ol.2024.14653. eCollection 2024 Nov.
3
Identification of feature genes and molecular mechanisms involved in cell communication in uveal melanoma through analysis of single‑cell sequencing data.
Oncol Lett. 2024 Aug 20;28(5):503. doi: 10.3892/ol.2024.14636. eCollection 2024 Nov.
4
Detection of neoplastic-immune hybrid cells with metastatic properties in uveal melanoma.
Biomark Res. 2024 Jul 20;12(1):67. doi: 10.1186/s40364-024-00609-6.
5
The multiple roles of autophagy in uveal melanoma and the microenvironment.
J Cancer Res Clin Oncol. 2024 Mar 11;150(3):121. doi: 10.1007/s00432-023-05576-3.
6
From Molecular Biology to Novel Immunotherapies and Nanomedicine in Uveal Melanoma.
Curr Oncol. 2024 Feb 1;31(2):778-800. doi: 10.3390/curroncol31020058.
7
Detection of neoplastic-immune hybrid cells with metastatic properties in uveal melanoma.
Res Sq. 2023 Dec 6:rs.3.rs-3694879. doi: 10.21203/rs.3.rs-3694879/v1.
8
Identification of co-expressed gene networks promoting CD8 T cell infiltration and having prognostic value in uveal melanoma.
BMC Ophthalmol. 2023 Aug 10;23(1):354. doi: 10.1186/s12886-023-03098-7.
9
Cross talk between tumor stemness and microenvironment for prognosis and immunotherapy of uveal melanoma.
J Cancer Res Clin Oncol. 2023 Oct;149(13):11951-11968. doi: 10.1007/s00432-023-05061-x. Epub 2023 Jul 7.
10
FGF-trapping hampers cancer stem-like cells in uveal melanoma.
Cancer Cell Int. 2023 May 11;23(1):89. doi: 10.1186/s12935-023-02903-z.
本文引用的文献
1
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study.
Lancet Oncol. 2019 Aug;20(8):1083-1097. doi: 10.1016/S1470-2045(19)30274-8. Epub 2019 Jun 17.
2
Pembrolizumab as first-line treatment for metastatic uveal melanoma.
Cancer Immunol Immunother. 2019 Jul;68(7):1179-1185. doi: 10.1007/s00262-019-02352-6. Epub 2019 Jun 7.
3
Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
J Immunother Cancer. 2019 Apr 8;7(1):100. doi: 10.1186/s40425-019-0565-5.
4
Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma.
J Oncol. 2018 Dec 2;2018:1908065. doi: 10.1155/2018/1908065. eCollection 2018.
5
Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumors.
Nat Commun. 2018 May 14;9(1):1866. doi: 10.1038/s41467-018-04322-5.
6
Programmed cell death ligand-1 expression in tumor and immune cells is associated with better patient outcome and decreased tumor-infiltrating lymphocytes in uveal melanoma.
Mod Pathol. 2018 Aug;31(8):1201-1210. doi: 10.1038/s41379-018-0043-5. Epub 2018 Mar 26.
7
Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT).
J Clin Oncol. 2018 Apr 20;36(12):1232-1239. doi: 10.1200/JCO.2017.74.1090. Epub 2018 Mar 12.
8
Role of immune checkpoint inhibitors and novel immunotherapies in uveal melanoma.
Chin Clin Oncol. 2018 Feb;7(1):8. doi: 10.21037/cco.2018.01.05.
9
Cellular and Molecular Mechanisms of Anterior Chamber-Associated Immune Deviation (ACAID): What We Have Learned from Knockout Mice.
Front Immunol. 2017 Nov 30;8:1686. doi: 10.3389/fimmu.2017.01686. eCollection 2017.
10
PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma.
Immunotherapy. 2017 Dec;9(16):1323-1330. doi: 10.2217/imt-2017-0066.
Zotero 插件